(I-BusinessNews.Com, March 15, 2019 ) Epigenetics Research Funding to Radiate a Cohort of Opportunities for Chronic Disease Treatments
Increasing funding for research and development for discovering therapeutic solutions continues to remain instrumental in product development pertaining to epigenetics space. With growing concerns regarding prevalence of chronic diseases such as cancer, diabetes and other metabolic diseases, organizations such as the National Institute of Health (NIH), National Cancer Institute (NCI) and the International Human Epigenome Consortium (IHEC) have encouraged advanced research in epigenetics field by undertaking new research initiatives such as the Epidemiology and Genomics Research Program. This factor has largely facilitated the novel therapeutic products, in turn supporting the epigenetics market.
Request Brochure of this Report@ https://www.factmr.com/connectus/sample?flag=B&rep_id=435
Epigenetics Gaining Ground in Cancer Therapeutics
Pervasiveness of epigenetics in biology has facilitated study of various alterations in gene expression that has played a vital role in understanding development of cancer cells and developing appropriate medications. Increasing prevalence of cancer cases worldwide have fuelled the need for advanced therapeutics to treat the chronic disease, which has influenced the growth of epigenetics market. For instance, World Health Organization (WHO) estimates that the cancer mortality rate in India has surpassed 79 per 100,000 deaths in the coming years. Likewise, American Cancer Society reveals that in 2017, United States reflected about 1,688,780 cancer cases and this figure is likely to increase in the future owing to improper lifestyle and high percentage of smoking and drinking. That said, the demand for cancer treatment and novel therapeutics has evolved to the next level using epigenetic research, which is likely to support the epigenetics market growth in the coming years.
Increasing Cardiovascular Diseases to Spearhead Epigenetics Demand
Prevalence of cardiovascular diseases (CVDs) was high in the past and is expected to further grow in the coming years owing to improper lifestyle and eating patterns. For instance, according to European Cardiovascular Disease Statistics, in 2017, cardiovascular diseases accounted for around 45 percent of deaths in the European countries. Japan is no exception to this, as deaths owing to heart related disorders have risen in the country, making it a subject of concern and high importance for medical practitioners there. Cardiovascular diseases have become pandemic with unhealthy lifestyle and excess consumption of food. Pervasiveness of this metabolic syndrome can be well addressed using novel therapies with epigenetics as their base. That said, increasing funding for research on therapies based on epigenetics for treating CVDs is expected to push the growth of the epigenetics market in the years to follow.
Get Free Exclusive Sample Copy of This Report @
https://www.factmr.com/connectus/sample?flag=S&rep_id=435
Epigenetics Facilitating New Generation of Diagnostics
Modifications in epigenetics are stable and offer strong signals acting as biomarkers for diseases that can be measured and mapped using HMCP platforms. Epigenetics biomarkers are largely specific for tissue type and disease state. According to scientific researchers, epigenetics can provide platforms for early detection of diseases as they can precede alterations in genetics. Minimally invasive techniques in combination with epigenetics platforms can provide informative tools that can facilitate swift and accurate diagnosis of diseases. With epigenetics as a novel diagnostic platform, a radical approach toward wellbeing management and long-term health can be envisaged allowing implementation of tailored clinical interventions, making diseases not inevitable, but optional.
Errors Causing Misleading Results in DNA-seq – A Critical Challenge
Albeit its high potential in diagnosis and development of novel therapeutics, epigenetics are associated with errors, especially with respect to the DIP-seq, a widely used method. Different cells in human body use different gene groups. This necessitates the use of additional signals in order to control the respective gene type used for that particular cell. DNA-seq, being attached to chemical groups processing such signals, is likely to make error in the epigenetic code, which can lead to misleading results. This aspect is likely to challenge the epigenetics market.
Report Analysis at https://www.factmr.com/report/435/epigenetics-market
Fact.MR
James Hilton
+353-1-6111-593
info@factmr.com
Source: EmailWire.Com 
